Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.

Gilead Sciences, Inc. GILD shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily.

Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89 billion for the quarter, above the Wall Street consensus of $4.45 billion.

Gilead said its projects total product sales between $30 billion and $31 billion this year, equal to what analysts were expecting, Reuters reports.

Separately, social media chatter is circulating that said Gilead Harvoni U.S. sales ($1.707 billion) missed expectations by over 20 percent, while international sales ($1.638 billion) beat by 80 percent.

These figures have not been verified by an analyst; Gilead has not yet returned a request for comment on this issue.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsGuidanceMoversTrading IdeasGeneralGileadGilead ReutersHarvoniSovaldi
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...